Host cell protein detection gap risk mitigation: quantitative IAC-MS for ELISA antibody reagent coverage determination
Host cell proteins (HCPs) must be sufficiently cleared from recombinant biopharmaceuticals during the downstream process (DSP) to ensure product quality, purity, and patient safety. For monitoring of HCP clearance, the typical method chosen is an enzyme-linked immunosorbent assay (ELISA) using polyc...
Main Authors: | Daniel M. Waldera-Lupa, Yvonne Jasper, Pia Köhne, Ronja Schwichtenhövel, Heiner Falkenberg, Thomas Flad, Peter Happersberger, Bernd Reisinger, Alireza Dehghani, Roland Moussa, Thomas Waerner |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-01-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2021.1955432 |
Similar Items
-
Polysaccharide-based chromatographic adsorbents for virus purification and viral clearance
by: Guy-Alain Junter, et al.
Published: (2020-08-01) -
Evaluation by ELISA of Anisakis simplex Larval Antigen Purified by Affinity Chromatography
by: M Rodero, et al.
Published: (2002-03-01) -
Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation
by: Leonor S. Castro, et al.
Published: (2021-04-01) -
Protocol for bevacizumab purification using Ac-PHQGQHIGVSK-agarose
by: Gabriela R. Barredo, et al.
Published: (2020-01-01) -
Biopharmaceutics applications in drug development /
by: Krishna, Rajesh, et al.
Published: (2008)